Coherent's Margin Expansion Aligns with Execution Thesis, Valuation Still Demanding

What happened

Coherent Corp. reported a notable improvement in profitability for Q1 FY27, with expanding margins reflecting stronger operational execution and cost efficiency, according to a recent article. This aligns with the company's ongoing ramp of 6-inch indium phosphide capacity, which was already boosting gross margin in prior quarters. However, the stock remains expensive at over 145 times earnings and 49 times EV/EBITDA, leaving minimal room for execution missteps. The article does not provide specific margin figures, so it is unclear whether the improvement exceeds the critical 39.6% non-GAAP threshold highlighted in the previous analysis. Consequently, while the news supports the operating thesis, it does not yet resolve concerns about cash conversion and valuation.

Implication

The margin expansion report supports Coherent's operating momentum, but the stock's high valuation leaves little room for error. Investors should verify that the Q1 FY27 gross margin exceeded the 39.6% non-GAAP level and that working capital and inventory trends are improving; otherwise, the rally may be unsustainable. A prudent approach is to wait for a pullback toward the attractive entry level of $285 or for two consecutive quarters of margin above 40% with moderating inventory growth. Long-term holders can maintain positions, but new capital should be deployed only if the company demonstrates free cash flow conversion. Monitoring hyperscaler capex and the 6-inch capacity ramp remains essential to assess the durability of margin expansion.

Thesis delta

The new evidence of margin expansion in Q1 FY27 confirms Coherent's manufacturing advantage is translating into higher profitability, modestly increasing confidence in the bull scenario. However, it does not alter the core valuation concern: the stock still trades at a significant premium to intrinsic value and requires sustained margin improvement and cash flow generation to justify its price. The WAIT rating remains appropriate until we see confirmation of free cash flow inflection.